Novo Nordisk Fires on Two Cylinders: Record Buyback and MASH Data Aim to Restore Investor Faith
21.05.2026 - 16:12:43 | boerse-global.de
Novo Nordisk is rolling out a two-pronged strategy to steady a stock that has been on a wild ride. The Danish pharma giant has unveiled its biggest share repurchase programme in recent memory while simultaneously gearing up to present pivotal data on semaglutide’s potential in metabolic liver disease. The timing is no accident: management wants to convince the market that the GLP-1 platform can still deliver growth even as competition intensifies and pricing pressures mount.
The buyback alone signals a boardroom that believes its own equity is undervalued. The total programme calls for 15 billion Danish kroner over twelve months from February 2026, with the second tranche — worth nearly 11.2 billion kroner — running from 6 May until February 2027. That is almost three times the size of the first tranche, which closed in May at 3.8 billion kroner. By 13 May, Novo had already bought back shares worth 4.17 billion kroner, taking its treasury stock to roughly 0.7% of issued capital.
The repurchase firepower is backed by stronger-than-expected quarterly numbers. In the first quarter, the newly launched oral Wegovy formulation generated 2.26 billion kroner in sales on 1.3 million prescriptions — nearly double analyst projections. The adjusted operating profit of 32.86 billion kroner beat estimates by about 4 billion kroner, and the combined Ozempic, Wegovy and Rybelsus franchise brought in 63.25 billion kroner, representing roughly 65% of total group revenue. Novo raised its full-year guidance on the back of the pill’s strong start, though it still expects adjusted sales and operating profit to decline by 4% to 12% in 2026 — a narrower range than previously flagged.
While the buyback shores up near-term sentiment, the pipeline story is getting a fresh chapter from the liver. At the EASL congress in Barcelona from 27 to 30 May, Novo will unveil new analyses from the ESSENCE programme evaluating semaglutide 2.4 mg in patients with metabolic dysfunction-associated steatohepatitis (MASH). The condition affects an estimated 250 million people worldwide and sits at the intersection of obesity and type 2 diabetes — exactly the territory Novo wants to dominate.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The data already on file are encouraging. In an interim analysis, 63% of Wegovy patients achieved MASH resolution without worsening of liver scarring, compared with 34% on placebo. Fibrosis improvement — a tougher endpoint — was seen in 37% of treated patients versus 22% in the control arm. The FDA has already granted accelerated approval for Wegovy in MASH with moderate to advanced fibrosis, but confirmatory data on hard outcomes such as death, liver transplant and liver-related events are still required.
Novo is also pushing beyond the GLP-1 molecule. A phase 1 trial is under way with Lexicon Pharmaceuticals for LX9851, an oral ACSL5 inhibitor that tackles fat metabolism through a different mechanism. The study involves 96 subjects and is expected to read out in the first quarter of 2027. Lexicon has already collected two $10 million milestone payments, with up to $1 billion in total potential payouts.
For all the positive noise, the stock remains in recovery mode. At €38.86, the shares have gained roughly 16% over the past month but are still down about 13% since the start of 2026. The trailing twelve-month decline is steeper at roughly 37%. The price sits about 10% above its 50-day moving average but well below the 200-day line, reflecting lingering scepticism about prescription trends for injectable GLP-1s and the competitive threat from Eli Lilly.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Regulatory uncertainty and price pressure remain wild cards. Novo’s next big forum will be the ADA conference on 7 June 2026, where management plans to update investors on pipeline progress and the broader strategy. For now, the buyback and MASH data serve as a double signal: the company is willing to put billions behind its own stock while simultaneously trying to prove that semaglutide can treat more than just diabetes and obesity. Whether that is enough to win back a wary market will become clearer after the Barcelona presentations.
Ad
Novo Nordisk Stock: New Analysis - 21 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
